Vyvanse Cost in Texas 2026: Brand, Generic, and Compounded Pricing

The real question is not the list price, it's which pricing mechanism applies to you

Most searches for "Vyvanse cost in Texas" assume there is one number to find. There isn't. The manufacturer's list price, the cash price at a given pharmacy, the insurance-negotiated rate, the Medicaid rate, and the compounded-pharmacy rate are five different pricing systems that rarely align. A Texas patient with commercial insurance and a Tier 1 generic fill pays a different order of magnitude than an uninsured patient paying cash for brand. The more useful question is which of those five pathways applies to your situation, because that determines the price far more than geography does.

The FDA has approved Vyvanse (lisdexamfetamine dimesylate) to treat ADHD in children age 6 and up, as well as moderate-to-severe binge eating disorder in adults. Because Vyvanse is classified as a Schedule II controlled substance, Texas has specific rules governing how doctors can prescribe it, process refills, and deliver it through telehealth services.

What brand and generic actually cost, and why the exact number keeps moving

Manufacturers periodically adjust list prices, and generic cash prices shift as more manufacturers enter the market after patent and exclusivity periods end. As a general pattern, once multiple generic manufacturers are approved for a given drug, cash-pay prices for that generic tend to fall substantially over the following one to two years compared with the newly-generic price. That pattern is well documented for prescription drugs broadly, but the specific current dollar amounts for brand Vyvanse and generic lisdexamfetamine in Texas should be checked directly with a pharmacy or a price-comparison tool (GoodRx, SingleCare, or similar) at the time of filling, since this article cannot certify a price as current.

What is stable: generic lisdexamfetamine must meet the same FDA bioequivalence standard as the brand product, meaning the active drug delivery is required to fall within the same approved range. The capsule's inactive ingredients and appearance can differ between manufacturers. A small number of patients report a perceived difference in symptom control after switching from brand to generic stimulants, though the underlying research on this specific question was not independently verified for this draft and should be confirmed against current literature before being cited as a settled finding.

Does Texas Medicaid cover Vyvanse?

Texas Medicaid covers lisdexamfetamine, but coverage of the brand product typically requires prior authorization, and Vyvanse is generally not treated as a preferred agent for ADHD. In practice this usually means a prescriber documents an inadequate response to, or intolerance of, a preferred stimulant (commonly a methylphenidate product) before Medicaid approves lisdexamfetamine, brand or generic.

Children enrolled in STAR or STAR Kids managed care add another layer: each managed care organization (Amerigroup, Superior HealthPlan, UnitedHealthcare Community Plan, and others) maintains its own formulary and prior authorization criteria within the state's overall Medicaid framework. Formularies are reviewed on a recurring cycle, so a plan's specific step-therapy requirement or preferred-agent list in one quarter is not guaranteed to hold in the next. Anyone relying on a specific approval rate, turnaround time, or approval percentage for Texas Medicaid prior authorizations should confirm it directly with the Texas Health and Human Services Commission or the relevant MCO, since this draft did not have a verified primary source for those specific figures.

Verification checklist: what's stable versus what you must reverify

Use this before acting on any specific number in this article or from a pharmacy quote.

If a number in this article conflicts with what you are quoted at a Texas pharmacy or told by an insurer, treat the real-time quote as authoritative.

How private insurance in Texas typically structures Vyvanse coverage

Commercial plans generally place generic lisdexamfetamine on a lower tier than brand Vyvanse, which is the standard pattern across most drug classes once a generic exists. Exact copay amounts, deductible interactions, and tier placement differ by employer plan and by insurer, and change at each plan renewal. A high-deductible health plan changes the math further: until the deductible is met, the patient generally pays the plan's negotiated rate rather than a flat copay, which for a brand stimulant can still be a meaningful monthly cost even though it is lower than the full list price.

Texas marketplace plans purchased through Healthcare.gov are subject to federal essential health benefit rules, which require covering at least one drug in a given pharmacologic class. That does not guarantee brand Vyvanse is the covered option; it may be satisfied by the generic.

How the Takeda savings card generally works, and who it excludes

Vyvanse's manufacturer, Takeda, has offered a copay assistance card for commercially insured patients. As a general structure, these manufacturer cards apply only to patients with active commercial insurance, exclude patients covered by Medicaid, Medicare, or TRICARE, and carry both a per-fill cap and an annual maximum benefit. The specific dollar figures for the current card (per-fill assistance amount, annual cap, and enrollment mechanics) should be confirmed on Takeda's current program page before a patient relies on them, since manufacturer card terms are revised periodically and this draft cannot certify the figures as current for 2026.

Uninsured patients are categorically excluded from manufacturer copay cards of this type; separate patient assistance programs, usually based on income, exist for that population and have their own eligibility rules that should be checked directly rather than assumed.

Is compounded lisdexamfetamine legal in Texas?

Yes, under narrow conditions. Texas 503A compounding pharmacies operate under the Texas Pharmacy Act and are subject to federal compounding law under Section 503A of the Federal Food, Drug, and Cosmetic Act, plus USP <795> standards for non-sterile compounding, enforced through Texas State Board of Pharmacy inspection (consistent with FDA compounding guidance).

A 503A pharmacy can compound lisdexamfetamine when a prescriber writes a patient-specific prescription for a documented clinical need that the commercial product cannot meet, such as a strength not manufactured commercially, a documented allergy to an inactive ingredient in the commercial capsule, or a liquid formulation for a patient who cannot take capsules. FDA guidance is explicit that a compounded product is treated as an impermissible copy of a commercially available drug if it is identical or nearly identical to the approved product without a documented medical reason for the difference. This means compounding is not a legal route to a cheaper version of ordinary-dose Vyvanse for patients who simply want to save money; it is intended for situations the commercial product does not cover.

Compounded lisdexamfetamine is generally not covered by standard pharmacy insurance benefits unless a plan carries a specific compounding rider, and pricing is set by the individual pharmacy rather than by a national list price. Anyone considering this route should confirm the pharmacy's current Texas State Board of Pharmacy license through the board's public verification tool before filling.

Can you get a Vyvanse prescription in Texas through telehealth?

Texas permits telehealth prescribing of Schedule II controlled substances, including lisdexamfetamine, when the prescriber holds an active Texas license and DEA registration and the encounter meets the applicable evaluation standard. Federal law under the Ryan Haight Act generally requires an in-person evaluation before a Schedule II prescription can be issued via telemedicine, with the DEA having authorized temporary flexibilities at various points; the current status of those flexibilities should be checked against DEA's own guidance before assuming a purely virtual pathway is available, since this has changed more than once in recent years.

Texas Medical Board rules governing telehealth ADHD evaluations generally require a synchronous audio-video visit rather than an audio-only call, along with documentation supporting the diagnosis and, for controlled substances, a check of the Texas Prescription Monitoring Program. Prescriptions for Schedule II drugs must generally be transmitted electronically under Texas and federal controlled-substance prescribing rules, with narrow paper exceptions.

Deciding the lowest-cost path for your situation

Commercially insured: Ask the prescriber to write for generic lisdexamfetamine first and check your plan's Tier 1 or Tier 2 copay before assuming brand is necessary. If brand is clinically necessary, check current Takeda savings card terms, since eligibility depends on active commercial coverage.

Uninsured: Generic lisdexamfetamine cash price is the usual floor. Compare pharmacy cash prices and discount-card rates (GoodRx, SingleCare, and similar tools aggregate negotiated rates) rather than assuming one pharmacy chain is cheapest across Texas. If the generic cash price is still unaffordable, ask about the manufacturer's patient assistance program and confirm current income eligibility criteria directly.

Texas Medicaid: Ask whether generic lisdexamfetamine avoids the prior authorization step your MCO applies to brand. If brand is medically necessary, the prior authorization request should document a prior trial of a preferred stimulant, since that is the general step-therapy pattern across Texas Medicaid MCOs.

Medicare Part D: Vyvanse is generally covered under Part D, with copay levels set by the specific plan; the Extra Help / Low-Income Subsidy program can lower copays for qualifying beneficiaries, but current dollar amounts should be checked against the plan's current year documents rather than assumed to be static from year to year.

What is established, what is plausible, and what is not established

Established: Vyvanse's FDA-approved indications, its Schedule II status, the bioequivalence standard generic manufacturers must meet, the general structure of 503A compounding law, and the general requirement that Schedule II telehealth prescribing meet a defined evaluation standard.

Plausible but not confirmed in this draft: specific current dollar figures for brand list price, generic cash price, Takeda card caps, and Texas Medicaid prior authorization approval rates. These numbers are the kind of thing insurers, manufacturers, and pharmacies revise on their own schedules, and none of the source citations available for this draft could be verified as current primary sources for those exact figures.

Not established here: any claim that switching between brand and generic lisdexamfetamine causes a measurable difference in clinical outcomes at the population level, and any specific percentage for Texas Medicaid prior authorization approval or denial rates. These require direct verification against Texas HHSC data or peer-reviewed literature before they can be stated as fact.